22 March 2017 in BioMed Research International
CMCristina Montero-Valladares
Cristina Montero-Valladares
+10
Objective. To determine the epidemiology and therapeutic management of patients with severe acute bronchiolitis (AB) admitted to paediatric intensive care units (PICUs) in Spain.Design. Descriptive, prospective, multicentre study.Setting. Sixteen Spanish PICUs.Patients. Patients with severe AB who required admission to any of the participating PICUs over 1 year.Interventions. Both epidemiological variables and medical treatment received were recorded.Results. A total of 262 patients were recruited; 143 were male (54.6%), with median age of 1 month (0–23). Median stay in the PICU was 7 days (1–46). Sixty patients (23%) received no nebuliser treatment, while the rest received a combination of inhalation therapies. One-quarter of patients (24.8%) received corticosteroids and 56.5% antibiotic therapy. High-flow oxygen therapy was used in 14.3% and noninvasive ventilation (NIV) was used in 75.6%. Endotracheal intubation was required in 24.4% of patients. Younger age, antibiotic therapy, and invasive mechanical ventilation (IMV) were risk factors that significantly increased the stay in the PICU.Conclusions. Spanish PICUs continue to routinely use nebulised bronchodilator treatment and corticosteroid therapy. Despite NIV being widely used in this condition, intubation was required in one-quarter of cases. Younger age, antibiotic therapy, and IMV were associated with a longer stay in the PICU.
17 November 2015 in PLOS ONE
MMMiguel A. Matamala-Morillo
Miguel A. Matamala-Morillo
PRPatricia Rodríguez-Campoy
Patricia Rodríguez-Campoy
B(Bronchiolitis of Cadiz Study group (BronCaS)
Bronchiolitis of Cadiz Study group (BronCaS)
+5
There is no evidence that the epinephrine-3% hypertonic saline combination is more effective than 3% hypertonic saline alone for treating infants hospitalized with acute bronchiolitis. We evaluated the efficacy of nebulized epinephrine in 3% hypertonic saline. We performed a randomized, double-blind, placebo-controlled clinical trial in 208 infants hospitalized with acute moderate bronchiolitis. Infants were randomly assigned to receive nebulized 3% hypertonic saline with either 3 mL of epinephrine or 3 mL of placebo, administered every four hours. The primary outcome measure was the length of hospital stay. A total of 185 infants were analyzed: 94 in the epinephrine plus 3% hypertonic saline group and 91 in the placebo plus 3% hypertonic saline group. Baseline demographic and clinical characteristics were similar in both groups. Length of hospital stay was significantly reduced in the epinephrine group as compared with the placebo group (3.94 ±1.88 days vs. 4.82 ±2.30 days, P = 0.011). Disease severity also decreased significantly earlier in the epinephrine group (P = 0.029 and P = 0.036 on days 3 and 5, respectively). In our setting, nebulized epinephrine in 3% hypertonic saline significantly shortens hospital stay in hospitalized infants with acute moderate bronchiolitis compared to 3% hypertonic saline alone, and improves the clinical scores of severity from the third day of treatment, but not before. EudraCT 2009-016042-57
30 September 2011 in Medicina Intensiva (English Edition)
27 May 2017 in Journal of Clinical Pharmacy and Therapeutics
AHArturo Hernández-González
Arturo Hernández-González
FRFernando Rubio-Quiñones
MSMónica Saldaña-Valderas
+1
27 November 2018 in Pediatric Drugs
PRPatricia Rodríguez-Campoy
Patricia Rodríguez-Campoy
MSMónica Saldaña-Valderas